TSUNO-GROUP
31.1.2024 08:16:27 CET | Business Wire | Press release
Tsuno Group Co., Ltd., headquartered in Katsuragi-cho, Ito-gun, Wakayama, and led by President: Fumi Tsuno and Matsumoto Trading Co., Ltd., headquartered in Chuo-ku, Tokyo, with CEO Shunsuke Matsumoto have successfully developed a new sunscreen formulation with Ferulic Acid. Ferulic Acid is a rare natural plant-derived UV absorber that has been difficult in stability and solubility at the high concentrations of ferulic acid.
For ferulic acid
Tsuno Group was the first in the world to successfully produce large amounts of ferulic acid, a polyphenol, from rice bran. Ferulic acid possesses strong antioxidant properties and has been recognized for its potential to prevent Alzheimer's disease, diabetes mellitus, and high cholesterol. It can also be used as a raw material for producing natural vanillin, a vanilla flavoring. In cosmetics, it inhibits melanin production by blocking tyrosinase activity and has anti-inflammatory, antimicrobial, and antioxidant properties. Therefore, it has been used as an active ingredient in a variety of cosmetic products.
“We, as a leading company in rice & bran chemistry in the world, have been developing a number of functional products with tremendous efforts through accumulating technologies, have also researched their safe levels and effects to be well accepted in pharma, food, feed and cosmetic industries. Now we have launched a technology of using ferulic acid from rice bran as a natural antioxidant and UV absorber, which is the first innovation ever in the world. We are confident that you shall discover this product as unique and impactful to contribute not only to the human health and beauty but the circular economy for the world.” —— Fumi Tsuno, President of Tsuno Group Co., Ltd.
UV absorption effect of ferulic acid
Ethylhexyl methoxycinnamate (EHMC), a petrochemical UV filter, is most widely used in sunscreen applications. However, recent studies have shown its negative impact on the aquatic environment, including coral bleaching. Ferulic acid, a naturally derived sunscreen ingredient from rice, absorbs UV rays in a similar range of the spectrum as octyl methoxycinnamate (OMC). This promising characteristic makes it a potential eco-friendly alternative to EHMC. Amidst growing global concerns about environmental sustainability, ferulic acid's potential as a natural and effective sunscreen ingredient is likely to gain increased recognition. It holds significant potential for application in a wide range of cosmetic products throughout Japan.
Development of high stability formulation of UV-care products with high concentration of Ferulic Acid
Gaining recognition for its UV-absorbing properties, ferulic acid, a rare natural plant-derived ingredient, presents challenges in solubility and stability at the high concentrations for sunscreen formulations. To overcome these hurdles, Matsumoto Trading has dedicated research and development, pioneering an innovative technology utilizing a high concentration of ferulic acid in a solid stick formulation. This novel formulation has been developed with SPF50+ and PA++ (in vitro) containing only ferulic acid, a natural UV absorber extracted from rice bran. This unique formulation eliminates the need for other commonly used UV protective ingredients, while maintaining high sun protection effectiveness. Patent pending.
About Tsuno Rice Fine Chemicals Co., Ltd.
Tsuno Rice Fine Chemicals manufactures various ingredients from by-products generated in the process of refining rice bran oil, and they can be used for pharmaceutical, cosmetic, functional foods, food additives, feedstock, and industrial chemicals. In addition, we are also engaged in the manufacture of cosmetics under our own brand that incorporate these ingredients.
Business Profile of Tsuno Group Co., Ltd.
We are promoting the advanced and effective use of rice bran, a symbol of health and beauty that has been popular since ancient times. We are developing three businesses: the Rice Bran Oil Production Business, the Fine Chemicals Business, and the Oleo Chemical Business.
Established: February 1, 1947
Representative Director and President Fumi Tsuno
URL : https://www.tsuno.co.jp/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130923907/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
